X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (19) 19
hiv infections - drug therapy (16) 16
female (15) 15
male (15) 15
adult (14) 14
hiv infections - virology (13) 13
infectious diseases (12) 12
middle aged (10) 10
viral load (10) 10
cd4 lymphocyte count (9) 9
anti-hiv agents - therapeutic use (8) 8
drug therapy (8) 8
drug therapy, combination (8) 8
hiv infections - immunology (8) 8
immunology (8) 8
antiretroviral therapy (7) 7
rna, viral - blood (7) 7
treatment outcome (7) 7
virology (7) 7
aged (6) 6
aids/hiv (6) 6
anti-hiv agents - administration & dosage (6) 6
anti-hiv agents - adverse effects (6) 6
double-blind method (6) 6
hiv (6) 6
hiv infection (6) 6
hiv-1 - genetics (6) 6
lamivudine (6) 6
therapy (6) 6
aids (5) 5
dideoxynucleosides - therapeutic use (5) 5
efficacy (5) 5
hiv-1 - drug effects (5) 5
ritonavir (5) 5
safety (5) 5
abacavir (4) 4
drug administration schedule (4) 4
hiv protease inhibitors - administration & dosage (4) 4
hiv protease inhibitors - adverse effects (4) 4
hiv-1 - isolation & purification (4) 4
lamivudine - administration & dosage (4) 4
lamivudine - therapeutic use (4) 4
abridged index medicus (3) 3
adenine - analogs & derivatives (3) 3
adenine - therapeutic use (3) 3
adherence (3) 3
adolescent (3) 3
alleles (3) 3
anti-retroviral agents - therapeutic use (3) 3
antiretrovirals (3) 3
antiviral agents (3) 3
care and treatment (3) 3
didanosine (3) 3
dideoxynucleosides - administration & dosage (3) 3
dideoxynucleosides - adverse effects (3) 3
double-blind (3) 3
drug resistance, viral (3) 3
health aspects (3) 3
hiv 1 (3) 3
hiv fusion inhibitors - therapeutic use (3) 3
hiv protease inhibitors - therapeutic use (3) 3
hiv-1 (3) 3
hiv/aids (3) 3
hla-b antigens - genetics (3) 3
indinavir (3) 3
lamivudine - adverse effects (3) 3
medicine, general & internal (3) 3
nelfinavir (3) 3
pharmacology & pharmacy (3) 3
research (3) 3
resistance (3) 3
ritonavir - administration & dosage (3) 3
rna (3) 3
stavudine (3) 3
tenofovir (3) 3
2008 recommendations (2) 2
adenine - adverse effects (2) 2
african americans - genetics (2) 2
amino acids (2) 2
anti-retroviral agents - adverse effects (2) 2
antiretroviral therapy, highly active - methods (2) 2
association (2) 2
atazanavir (2) 2
atazanavir sulfate (2) 2
ccr5 receptor antagonists (2) 2
cyclohexanes - adverse effects (2) 2
cyclohexanes - therapeutic use (2) 2
disease progression (2) 2
dolutegravir (2) 2
dosage and administration (2) 2
drug resistance (2) 2
efavirenz (2) 2
etravirine (2) 2
genotype (2) 2
hiv envelope protein gp41 - therapeutic use (2) 2
hiv fusion inhibitors - adverse effects (2) 2
hiv infections - genetics (2) 2
hiv patients (2) 2
hiv-1 - chemistry (2) 2
hiv-1 - immunology (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 10/2008, Volume 359, Issue 14, pp. 1442 - 1455
In key subgroups of the HIV-infected patients in the MOTIVATE 1 and MOTIVATE 2 studies, a consistent treatment benefit of maraviroc over placebo was seen at 48... 
CCR5 ANTAGONIST | MEDICINE, GENERAL & INTERNAL | VIRUS | EFFICACY | HEPATITIS | EXPERIENCED HIV-1-INFECTED PATIENTS | TMC125 ETRAVIRINE | ACTIVE ANTIRETROVIRAL THERAPY | DRUG-RESISTANT HIV-1 | DOUBLE-BLIND | PROGNOSTIC VALUE | Triazoles - adverse effects | Humans | Middle Aged | Receptors, CCR5 - genetics | Male | RNA, Viral - blood | Hepatitis B - blood | Viral Load | Hepatitis B - complications | Cyclohexanes - therapeutic use | HIV Infections - immunology | Ethnic Groups | Enfuvirtide | Maraviroc | HIV Envelope Protein gp41 - therapeutic use | HIV-1 - chemistry | Hepatitis C - blood | Adult | Female | Hepatitis C - complications | Cyclohexanes - adverse effects | Drug Therapy, Combination | Odds Ratio | CCR5 Receptor Antagonists | Triazoles - therapeutic use | Anti-Retroviral Agents - therapeutic use | Double-Blind Method | HIV Infections - virology | Anti-Retroviral Agents - adverse effects | Genotype | Treatment Outcome | CD4 Lymphocyte Count | HIV Fusion Inhibitors - adverse effects | HIV-1 - genetics | HIV Fusion Inhibitors - therapeutic use | HIV Infections - drug therapy | Transaminases - blood | Aged | Peptide Fragments - therapeutic use | Antiviral agents | Care and treatment | Comparative analysis | Health aspects | HIV infection | Drug therapy | Drug resistance | Human immunodeficiency virus--HIV | Chemokines | Index Medicus | Abridged Index Medicus
Journal Article
by Pereyra, Florencia and Jia, Xiaoming and McLaren, Paul J and Telenti, Amalio and de Bakker, Paul I. W and Walker, Bruce D and Ripke, Stephan and Brumme, Chanson J and Pulit, Sara L and Carrington, Mary and Kadie, Carl M and Carlson, Jonathan M and Heckerman, David and Graham, Robert R and Plenge, Robert M and Deeks, Steven G and Gianniny, Lauren and Crawford, Gabriel and Sullivan, Jordan and Gonzalez, Elena and Davies, Leela and Camargo, Amy and Moore, Jamie M and Beattie, Nicole and Gupta, Supriya and Crenshaw, Anew and Burtt, Noël P and Guiducci, Candace and Gupta, Namrata and Gao, Xiaojiang and Qi, Ying and Yuki, Yuko and Piechocka-Trocha, Alicja and Cutrell, Emily and Rosenberg, Rachel and Moss, Kristin L and Lemay, Paul and O'Leary, Jessica and Schaefer, Todd and Verma, Pranshu and Toth, Ildiko and Block, Brian and Baker, Brett and Rothchild, Alissa and Lian, Jeffrey and Proudfoot, Jacqueline and Alvino, Donna Marie L and Vine, Seanna and Addo, Marylyn M and Allen, Todd M and Altfeld, Marcus and Henn, Matthew R and Le Gall, Sylvie and Streeck, Henik and Haas, David W and Kuritzkes, Daniel R and Robbins, Gregory K and Shafer, Robert W and Gulick, Roy M and Shikuma, Cecilia M and Haubrich, Richard and Riddler, Sharon and Sax, Paul E and Daar, Eric S and Ribaudo, Heather J and Agan, Brian and Agarwal, Shanu and Ahern, Richard L and Allen, Brady L and Altidor, Sherly and Altschuler, Eric L and Ambardar, Sujata and Anastos, Kathryn and Anderson, Ben and Anderson, Val and Anady, Ushan and Antoniskis, Diana and Bangsberg, David and Barbaro, Daniel and Barrie, William and Bartczak, J and Barton, Simon and Basden, Patricia and Basgoz, Nesli and Bazner, Suzane and Bellos, Nicholaos C and Benson, Anne M and Berger, Judith and Bernard, Nicole F and Bernard, Annette M and Birch, Christopher and Bodner, Stanley J and Bolan, Robert K and Boueaux, Emilie T and Bradley, Meg and Braun, James F and Brndjar, Jon E and Brown, Stephen J and Brown, Katherine and Brown, Sheldon T and ... and The International HIV Controllers Study and Int HIV Controllers Study and International HIV Controllers Study
Science (American Association for the Advancement of Science), ISSN 1095-9203, 2010, Volume 330, Issue 6010, pp. 1551 - 1557
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 10/2008, Volume 359, Issue 14, pp. 1429 - 1441
Journal Article
Journal Article
Journal Article
AIDS, ISSN 0269-9370, 07/2009, Volume 23, Issue 12, pp. 1547 - 1556
Background: Abacavir sulfate/lamivudine (ABC/3TC) and tenofovir DF/emtricitabine (TDF/FTC) are widely used nucleoside reverse transcriptase inhibitors for... 
Emtricitabine | Tenofovir | Ritonavir | Lopinavir | Abacavir | Lamivudine | Antiretroviral therapy | emtricitabine | INFECTIOUS DISEASES | MYOCARDIAL-INFARCTION | tenofovir | antiretroviral therapy | NAIVE HIV-1-INFECTED PATIENTS | IMMUNOLOGY | REVERSE-TRANSCRIPTASE INHIBITORS | VIROLOGY | lopinavir | ritonavir | RENAL-FAILURE | abacavir | SOCIETY-USA PANEL | INFECTED PATIENTS | 2008 RECOMMENDATIONS | FANCONI-SYNDROME | lamivudine | Humans | Antiretroviral Therapy, Highly Active - adverse effects | Male | RNA, Viral - blood | Lamivudine - adverse effects | HIV Infections - immunology | Deoxycytidine - therapeutic use | Adenine - adverse effects | Ritonavir - adverse effects | Adenine - therapeutic use | HIV-1 - isolation & purification | Lamivudine - therapeutic use | Ritonavir - therapeutic use | Adult | Anti-HIV Agents - therapeutic use | Deoxycytidine - adverse effects | Female | Dideoxynucleosides - adverse effects | Dideoxynucleosides - therapeutic use | Antiretroviral Therapy, Highly Active - methods | Adenine - analogs & derivatives | Double-Blind Method | Organophosphonates - therapeutic use | Anti-HIV Agents - adverse effects | HIV Infections - virology | Pyrimidinones - adverse effects | Pyrimidinones - therapeutic use | Organophosphonates - adverse effects | Treatment Outcome | CD4 Lymphocyte Count | HIV-1 - genetics | HIV Infections - drug therapy | Cardiovascular Diseases - chemically induced | Deoxycytidine - analogs & derivatives | Index Medicus | AIDS/HIV
Journal Article
The Journal of infectious diseases, ISSN 0022-1899, 4/2005, Volume 191, Issue 7, pp. 1155 - 1163
Journal Article
Journal Article